Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity
- PMID: 34512295
- PMCID: PMC8427803
- DOI: 10.3389/fnhum.2021.708481
Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity
Abstract
Deep brain stimulation (DBS) represents an important treatment modality for movement disorders and other circuitopathies. Despite their miniaturization and increasing sophistication, DBS systems share a common set of components of which the implantable pulse generator (IPG) is the core power supply and programmable element. Here we provide an overview of key hardware and software specifications of commercially available IPG systems such as rechargeability, MRI compatibility, electrode configuration, pulse delivery, IPG case architecture, and local field potential sensing. We present evidence-based approaches to mitigate hardware complications, of which infection represents the most important factor. Strategies correlating positively with decreased complications include antibiotic impregnation and co-administration and other surgical considerations during IPG implantation such as the use of tack-up sutures and smaller profile devices.Strategies aimed at maximizing battery longevity include patient-related elements such as reliability of IPG recharging or consistency of nightly device shutoff, and device-specific such as parameter delivery, choice of lead configuration, implantation location, and careful selection of electrode materials to minimize impedance mismatch. Finally, experimental DBS systems such as ultrasound, magnetoelectric nanoparticles, and near-infrared that use extracorporeal powered neuromodulation strategies are described as potential future directions for minimally invasive treatment.
Keywords: DBS (deep brain stimulation); IPG (implantable pulse generator); battery life; complications; longevity; neuromodulation; non-invasive; wireless charging.
Copyright © 2021 Sarica, Iorio-Morin, Aguirre-Padilla, Najjar, Paff, Fomenko, Yamamoto, Zemmar, Lipsman, Ibrahim, Hamani, Hodaie, Lozano, Munhoz, Fasano and Kalia.
Conflict of interest statement
AL has consulted for Medtronic, Abbott, Boston Scientific, Insightec, Aleva and is a co-founder of Functional Neuromodulation. SK received consulting fees from Medtronic. CS has received fellowship grants from Michael and Amira Dan Foundation and Turkish Neurosurgical Society. CI-M is founder and CEO of Hyperexis and Abaxial Médical Inc. AF reports the following: consultancies from Abbvie, Medtronic, Boston Scientific, Sunovion, Chiesi farmaceutici, UCB, Ipsen; Advisory Boards of Abbvie, Boston Scientific, Ipsen; honoraria from Abbvie, Medtronic, Boston Scientific, Sunovion, Chiesi farmaceutici, UCB, Ipsen; grants from University of Toronto, Weston foundation, Abbvie, Medtronic, Boston Scientific. RM is in the advisory board of Medtronic and receives grants from Medtronic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


References
-
- Akbar U., Raike R. S., Hack N., Hess C. W., Skinner J., Martinez-Ramirez D., et al. . (2016). Randomized, blinded pilot testing of nonconventional stimulation patterns and shapes in Parkinson’s disease and essential tremor: evidence for further evaluating narrow and biphasic pulses. Neuromodulation 19, 343–356. 10.1111/ner.12397 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources